Academic Journal
Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer
| العنوان: | Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer |
|---|---|
| المؤلفون: | Sobhani N., D'Angelo A., Pittacolo M., Roviello G., Miccoli A., Corona S. P., Bernocchi O., Generali D., Otto T. |
| المساهمون: | Sobhani, N., D'Angelo, A., Pittacolo, M., Roviello, G., Miccoli, A., Corona, S. P., Bernocchi, O., Generali, D., Otto, T. |
| سنة النشر: | 2019 |
| المجموعة: | Università degli studi di Trieste: ArTS (Archivio della ricerca di Trieste) |
| مصطلحات موضوعية: | breast cancer, cyclin-dependent kinase 4 and 6 inhibitor, cyclin-dependent kinase, targeted therapies |
| الوصف: | Breast Cancer (BC) is the second most common type of cancer worldwide and displays the highest cancer-related mortality among women worldwide. Targeted therapies have revolutionized the way BC has been treated in recent decades, improving the life expectancies of millions of women. Among the different molecular pathways that have been of interest for the development of targeted therapies are the Cyclin-Dependent Kinases (CDK). CDK inhibitors are a class of molecules that already exist in nature and those belonging to the Cyclin dependent kinase inhibitors family INK4 that specifically inhibit CDK4/6 proteins. CDK4/6 inhibitors specifically block the transition from the G1 to the S phase of the cell cycle by dephosphorylation of the retinoblastoma tumor suppressor protein. In the past four years, the CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, received their first FDA approval for the treatment of Hormone Receptor (HR)-positive and Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer after showing significant improvements in progression-free survival in the PALOMA-1, MONALEESA-2 and the MONARCH-2 randomized clinical trials, respectively. After the encouraging results from these clinical trials, CDK4/6 inhibitors have also been investigated in other BC subtypes. In HER2-positive BC, a combination of CDK4/6 inhibitors with HER2-targeted therapies showed promise in preclinical studies and their clinical evaluation is ongoing. Moreover, in triple-negative BC, the efficacy of CDK4/6 inhibitors has been investigated in combination with other targeted therapies or immunotherapies. This review summarizes the molecular background and clinical efficacy of CDK4/6 inhibitors as single agents or in combination with other targeted therapies for the treatment of BC. Future directions for ongoing clinical trials and predictive biomarkers will be further debated. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/30959874; info:eu-repo/semantics/altIdentifier/wos/WOS:000467304300035; volume:8; issue:4; firstpage:"-"; lastpage:"-"; numberofpages:24; journal:CELLS; https://hdl.handle.net/11368/3053139; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85067212188; https://www.mdpi.com/2073-4409/8/4/321; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523967/ |
| DOI: | 10.3390/cells8040321 |
| الاتاحة: | https://hdl.handle.net/11368/3053139 https://doi.org/10.3390/cells8040321 https://www.mdpi.com/2073-4409/8/4/321 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523967/ |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.F63EF144 |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.F63EF144 893 3 Academic Journal academicJournal 892.664306640625 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.F63EF144&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://hdl.handle.net/11368/3053139# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Sobhani+N%2E%22">Sobhani N.</searchLink><br /><searchLink fieldCode="AR" term="%22D'Angelo+A%2E%22">D'Angelo A.</searchLink><br /><searchLink fieldCode="AR" term="%22Pittacolo+M%2E%22">Pittacolo M.</searchLink><br /><searchLink fieldCode="AR" term="%22Roviello+G%2E%22">Roviello G.</searchLink><br /><searchLink fieldCode="AR" term="%22Miccoli+A%2E%22">Miccoli A.</searchLink><br /><searchLink fieldCode="AR" term="%22Corona+S%2E+P%2E%22">Corona S. P.</searchLink><br /><searchLink fieldCode="AR" term="%22Bernocchi+O%2E%22">Bernocchi O.</searchLink><br /><searchLink fieldCode="AR" term="%22Generali+D%2E%22">Generali D.</searchLink><br /><searchLink fieldCode="AR" term="%22Otto+T%2E%22">Otto T.</searchLink> ) Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => Sobhani, N.<br />D'Angelo, A.<br />Pittacolo, M.<br />Roviello, G.<br />Miccoli, A.<br />Corona, S. P.<br />Bernocchi, O.<br />Generali, D.<br />Otto, T. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2019 ) Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => Università degli studi di Trieste: ArTS (Archivio della ricerca di Trieste) ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22breast+cancer%22">breast cancer</searchLink><br /><searchLink fieldCode="DE" term="%22cyclin-dependent+kinase+4+and+6+inhibitor%22">cyclin-dependent kinase 4 and 6 inhibitor</searchLink><br /><searchLink fieldCode="DE" term="%22cyclin-dependent+kinase%22">cyclin-dependent kinase</searchLink><br /><searchLink fieldCode="DE" term="%22targeted+therapies%22">targeted therapies</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Breast Cancer (BC) is the second most common type of cancer worldwide and displays the highest cancer-related mortality among women worldwide. Targeted therapies have revolutionized the way BC has been treated in recent decades, improving the life expectancies of millions of women. Among the different molecular pathways that have been of interest for the development of targeted therapies are the Cyclin-Dependent Kinases (CDK). CDK inhibitors are a class of molecules that already exist in nature and those belonging to the Cyclin dependent kinase inhibitors family INK4 that specifically inhibit CDK4/6 proteins. CDK4/6 inhibitors specifically block the transition from the G1 to the S phase of the cell cycle by dephosphorylation of the retinoblastoma tumor suppressor protein. In the past four years, the CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, received their first FDA approval for the treatment of Hormone Receptor (HR)-positive and Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer after showing significant improvements in progression-free survival in the PALOMA-1, MONALEESA-2 and the MONARCH-2 randomized clinical trials, respectively. After the encouraging results from these clinical trials, CDK4/6 inhibitors have also been investigated in other BC subtypes. In HER2-positive BC, a combination of CDK4/6 inhibitors with HER2-targeted therapies showed promise in preclinical studies and their clinical evaluation is ongoing. Moreover, in triple-negative BC, the efficacy of CDK4/6 inhibitors has been investigated in combination with other targeted therapies or immunotherapies. This review summarizes the molecular background and clinical efficacy of CDK4/6 inhibitors as single agents or in combination with other targeted therapies for the treatment of BC. Future directions for ongoing clinical trials and predictive biomarkers will be further debated. ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => ELETTRONICO ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => info:eu-repo/semantics/altIdentifier/pmid/30959874; info:eu-repo/semantics/altIdentifier/wos/WOS:000467304300035; volume:8; issue:4; firstpage:"-"; lastpage:"-"; numberofpages:24; journal:CELLS; https://hdl.handle.net/11368/3053139; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85067212188; https://www.mdpi.com/2073-4409/8/4/321; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523967/ ) Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.3390/cells8040321 ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://hdl.handle.net/11368/3053139<br />https://doi.org/10.3390/cells8040321<br />https://www.mdpi.com/2073-4409/8/4/321<br />https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523967/ ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => info:eu-repo/semantics/openAccess ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.F63EF144 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.3390/cells8040321
)
)
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => breast cancer
[Type] => general
)
[1] => Array
(
[SubjectFull] => cyclin-dependent kinase 4 and 6 inhibitor
[Type] => general
)
[2] => Array
(
[SubjectFull] => cyclin-dependent kinase
[Type] => general
)
[3] => Array
(
[SubjectFull] => targeted therapies
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sobhani N.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => D'Angelo A.
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pittacolo M.
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Roviello G.
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Miccoli A.
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Corona S. P.
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bernocchi O.
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Generali D.
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Otto T.
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Sobhani, N.
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => D'Angelo, A.
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pittacolo, M.
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Roviello, G.
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Miccoli, A.
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Corona, S. P.
)
)
)
[15] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bernocchi, O.
)
)
)
[16] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Generali, D.
)
)
)
[17] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Otto, T.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2019
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsbas.oa
)
)
)
)
)
)
)
|
| IllustrationInfo |